RT Journal Article
T1 A dalbavancin lock solution can reduce enterococcal biofilms after freezing
A1 Díaz Navarro, Marta
A1 Hafian, Rama
A1 Manzano, Irene
A1 Pérez Granda, María Jesús
A1 Cercenado Mansilla, Emilia
A1 Pascual, Cristina
A1 Rodríguez, Carmen
A1 Muñoz, Patricia
A1 Guembe Ramírez, María
AB Introduction: We previously demonstrated the efficacy of a frozen dalbavancin–heparin (DH) lock solution against biofilms of staphylococci. However, as enterococci also commonly cause catheter-related bloodstream infections (CRBSI), we assessed the bioactivity of frozen dalbavancin (D) and DH against enterococci.Methods: Over 6 months, we compared the bioactivity of a solution of DH (1 mg/ml) with that of D in terms of cfu counts and metabolic activity against biofilms of Enterococcus faecalis and Enterococcus faecium (four strains each). For each solution, we individually compared results obtained at each time point (months 3 and 6) with baseline (month 0). We also compared the median DH value of each variable at baseline and at months 3 and 6 of freezing with the values obtained for D alone. We used both statistical and clinical criteria when results were within 25% of the reference value. Results: At the end of the experiment (month 6), neither a statistically nor a clinically significant reduction in the bioactivity of D solution was observed in terms of cfu count and metabolic activity against enterococcal biofilms. Regarding the DH solution, we found both statistical and clinical significance in the median percentage reduction in metabolic activity between months 0 and 6 in E. faecalis strains (51.8% vs. 77.8%, P = 0.007). Moreover, after freezing, the DH solution lost significant bioactivity compared with the D solution, especially in E. faecalis.Conclusion: A dalbavancin lock solution can be frozen for up to 6 months with no negative effect on its bioactivity against enterococcal biofilms. However, when combined with heparin, its  efficacy was reduced. Therefore, we recommend that if lock therapy with frozen dalbavancin is used in the management of enterococcal C-RBSI, heparin should be added simultaneously at the time of catheter lock.
PB Springer
SN 2193-8229
YR 2022
FD 2022-01-16
LK https://hdl.handle.net/20.500.14352/72066
UL https://hdl.handle.net/20.500.14352/72066
LA eng
NO Díaz-Navarro M, Hafian R, Manzano I, Pérez-Granda MJ, Cercenado E, Pascual C, et al. A Dalbavancin Lock Solution Can Reduce Enterococcal Biofilms After Freezing. Infect Dis Ther 2022;11:743–55. https://doi.org/10.1007/s40121-021-00579-4.
NO Ministerio de Ciencia, Innovación y Universidades (España)/Instituto de Salud Carlos III
NO Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional
NO Consejería de Educación, Juventud y Deporte (Comunidad de Madrid)/ Fondo Social Europeo
DS Docta Complutense
RD 21 abr 2025